149 related articles for article (PubMed ID: 28560396)
1. Mitochondrial Ca2+ removal amplifies TRAIL cytotoxicity toward apoptosis-resistant tumor cells via promotion of multiple cell death modalities.
Takata N; Ohshima Y; Suzuki-Karasaki M; Yoshida Y; Tokuhashi Y; Suzuki-Karasaki Y
Int J Oncol; 2017 Jul; 51(1):193-203. PubMed ID: 28560396
[TBL] [Abstract][Full Text] [Related]
2. Disrupting mitochondrial Ca2+ homeostasis causes tumor-selective TRAIL sensitization through mitochondrial network abnormalities.
Ohshima Y; Takata N; Suzuki-Karasaki M; Yoshida Y; Tokuhashi Y; Suzuki-Karasaki Y
Int J Oncol; 2017 Oct; 51(4):1146-1158. PubMed ID: 28849210
[TBL] [Abstract][Full Text] [Related]
3. Autophagy inhibitors regulate TRAIL sensitivity in human malignant cells by targeting the mitochondrial network and calcium dynamics.
Onoe-Takahashi A; Suzuki-Karasaki M; Suzuki-Karasaki M; Ochiai T; Suzuki-Karasaki Y
Int J Oncol; 2019 May; 54(5):1734-1746. PubMed ID: 30896851
[TBL] [Abstract][Full Text] [Related]
4. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
[TBL] [Abstract][Full Text] [Related]
5. Plasma-stimulated medium kills TRAIL-resistant human malignant cells by promoting caspase-independent cell death via membrane potential and calcium dynamics modulation.
Tokunaga T; Ando T; Suzuki-Karasaki M; Ito T; Onoe-Takahashi A; Ochiai T; Soma M; Suzuki-Karasaki Y
Int J Oncol; 2018 Mar; 52(3):697-708. PubMed ID: 29393427
[TBL] [Abstract][Full Text] [Related]
6. Cold PSM, but not TRAIL, triggers autophagic cell death: A therapeutic advantage of PSM over TRAIL.
Ito T; Ando T; Suzuki-Karasaki M; Tokunaga T; Yoshida Y; Ochiai T; Tokuhashi Y; Suzuki-Karasaki Y
Int J Oncol; 2018 Aug; 53(2):503-514. PubMed ID: 29845256
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.
Mühlethaler-Mottet A; Flahaut M; Bourloud KB; Auderset K; Meier R; Joseph JM; Gross N
BMC Cancer; 2006 Aug; 6():214. PubMed ID: 16930472
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial division inhibitor-1 induces mitochondrial hyperfusion and sensitizes human cancer cells to TRAIL-induced apoptosis.
Akita M; Suzuki-Karasaki M; Fujiwara K; Nakagawa C; Soma M; Yoshida Y; Ochiai T; Tokuhashi Y; Suzuki-Karasaki Y
Int J Oncol; 2014 Nov; 45(5):1901-12. PubMed ID: 25174275
[TBL] [Abstract][Full Text] [Related]
9. Epoxomicin Sensitizes Resistant Osteosarcoma Cells to TRAIL Induced Apoptosis.
Hanikoglu F; Cort A; Ozben H; Hanikoglu A; Ozben T
Anticancer Agents Med Chem; 2015; 15(4):527-33. PubMed ID: 25666501
[TBL] [Abstract][Full Text] [Related]
10. TRAIL-mediated apoptosis requires NF-kappaB inhibition and the mitochondrial permeability transition in human hepatoma cells.
Kim YS; Schwabe RF; Qian T; Lemasters JJ; Brenner DA
Hepatology; 2002 Dec; 36(6):1498-508. PubMed ID: 12447876
[TBL] [Abstract][Full Text] [Related]
11. Sensitization of multidrug resistant human ostesarcoma cells to Apo2 Ligand/TRAIL-induced apoptosis by inhibition of the Akt/PKB kinase.
Cenni V; Maraldi NM; Ruggeri A; Secchiero P; Del Coco R; De Pol A; Cocco L; Marmiroli S
Int J Oncol; 2004 Dec; 25(6):1599-608. PubMed ID: 15547696
[TBL] [Abstract][Full Text] [Related]
12. Diallyl trisulfide sensitizes human melanoma cells to TRAIL-induced cell death by promoting endoplasmic reticulum-mediated apoptosis.
Murai M; Inoue T; Suzuki-Karasaki M; Ochiai T; Ra C; Nishida S; Suzuki-Karasaki Y
Int J Oncol; 2012 Dec; 41(6):2029-37. PubMed ID: 23064375
[TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria.
Zhang XD; Zhang XY; Gray CP; Nguyen T; Hersey P
Cancer Res; 2001 Oct; 61(19):7339-48. PubMed ID: 11585775
[TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibitor MG132 enhances TRAIL-induced apoptosis and inhibits invasion of human osteosarcoma OS732 cells.
Li X; Huang T; Jiang G; Gong W; Qian H; Zou C
Biochem Biophys Res Commun; 2013 Sep; 439(2):179-86. PubMed ID: 23994633
[TBL] [Abstract][Full Text] [Related]
15. Induction of apoptosis in osteogenic sarcoma cells by combination of tumor necrosis factor-related apoptosis inducing ligand and chemotherapeutic agents.
Sun J; Fu ZM; Fang CQ; Li JH
Chin Med J (Engl); 2007 Mar; 120(5):400-4. PubMed ID: 17376311
[TBL] [Abstract][Full Text] [Related]
16. A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma.
Ndozangue-Touriguine O; Sebbagh M; Mérino D; Micheau O; Bertoglio J; Bréard J
Oncogene; 2008 Oct; 27(46):6012-22. PubMed ID: 18560353
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential.
Hotta T; Suzuki H; Nagai S; Yamamoto K; Imakiire A; Takada E; Itoh M; Mizuguchi J
J Orthop Res; 2003 Sep; 21(5):949-57. PubMed ID: 12919886
[TBL] [Abstract][Full Text] [Related]
18. Synergistic effect of celecoxib in tumor necrosis factor‑related apoptosis‑inducing ligand treatment in osteosarcoma cells.
Liu G; Yu MY; Huang X; Zhu D; Cheng S; Ma R; Gu G
Mol Med Rep; 2014 Oct; 10(4):2198-202. PubMed ID: 25050836
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells.
Wang P; Zhang J; Bellail A; Jiang W; Hugh J; Kneteman NM; Hao C
Cell Signal; 2007 Nov; 19(11):2237-46. PubMed ID: 17693058
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells.
Walczak H; Bouchon A; Stahl H; Krammer PH
Cancer Res; 2000 Jun; 60(11):3051-7. PubMed ID: 10850456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
